Home News Weather Finance Travel Maps Movies Lottery Horoscopes Games
 SECTION: HIV & AIDS RESEARCH, POLITICS
Search The Web:
DOMAIN NAMES
AS LOW AS $2.99 / YR.
Health Officials Cancel HIV Vaccine Trial
Friday, 18-Jul-2008 1:14PM United Press International
USTINET NEWS

 » Front Page

 » Top Stories

 » U.S.

 » World

 » Politics

 » Business

 » Sports

 » Health

 » Tech/Science

    Aerospace & NASA

    Computers

    Electronics

    Environment

    Nuclear

    Science

    Telecomm

 » Living/Entertainment

 » Off Beat Stories

 » News Photos

 » Weather


Special Editions

 » Iraq & Conflict

 » Israel/Palestine

 » Crimes & Laws


MultiMedia

 » Interactive Features

 » News Photos


POLL: Your Opinion

 » What Do You Think




BETHESDA, Md., July 18 (UPI) -- Health officials canceled a U.S. human trial of a human immunodeficiency virus vaccine, saying the size and scope of the proposed trial was too large.

SAVE MONEY ON TRAVEL DEALS

"After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases ... has determined that it will not conduct the HIV vaccine study known as PAVE 100", the National Institutes of Health division said Thursday in a news release.

"However, ... NIAID will entertain a proposal for an alternative study with one specific goal: to determine if the vaccine regimen significantly lowers viral load -- the amount of HIV in the blood of vaccinated individuals who may later become infected with HIV", the virus that causes AIDS, the agency said.

PAVE, the Partnership for AIDS Vaccine Evaluation, is a consortium of U.S. government agencies and government-funded organizations involved in developing and evaluating experimental HIV vaccines that might not be developed by pharmaceutical companies or institutions on their own.

The trial was supposed to have begun enrolling 8,500 volunteers last October to receive the vaccine, The New York Times reported. It was delayed after a test of a similar vaccine made by Merck failed in its two main goals: infection prevention and lowing the amount of HIV in the blood in volunteers who became infected.

Also, findings among the 3,000 participants in nine countries where the Merck vaccine was tested suggested it might have increased the risk of volunteers of becoming infected with HIV, the Times said.

- - - - - - - - - - - - - - - - - - - -
Related News Topics:

HIV and AIDS research, politics
Top science, technical and computer stories
Disease, medicine, health care research
Miscellaneous science and technology stories
Disease, medicine, aids, health care research

 BREAKING STORIES

Nobel Prize in medicine awarded to three

CDC: More than 1 million have HIV in U.S.

Risky TV sexual behavior may be modeled

Expert: Media pressures teens to have sex

Prostitute jailed for soliciting with HIV

Men 'on the down low' fear disclosure

Cost-effective HIV monitoring system found

Meek immune response helps AIDS survival

Long term sought for HIV-secretive man

Study evaluates HIV genetic screening

Florida doctors guilty of Medicare fraud

CDC: Blacks, gays most at risk for HIV

Calif. man to get his 'HIV' vanity plate

STDs increase HIV risk if exposed

Iran arrests chill anti-AIDS exchanges

Study: Why U.S. teens don't use condoms

Swaziland king's lavish lifestyle slammed

Brain cells may attack immune system

Increase in bone fractures linked to HIV

NYC HIV spreading at triple the U.S. rate

Home News Weather Finance Travel Maps Movies Lottery Horoscopes Games
Home :: My Page :: My WebMail :: My Calendar :: My Portfolio :: Chat :: Help Center :: Sign In :: Sign Out

MY.USTI.NET PORTAL  -  © 1996 - 2004 USTINET CORPORATION. ALL RIGHTS RESERVED.
Please see our Privacy Policy, Security Guarantee, Terms of Use for additional information.